Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metronomic Decitabine/Cedazuridine Plus Venetoclax in AML Maintenance
NCT07867626Phase 2Not yet recruiting
- Sponsor
- Rutgers University
- Start
- Sep 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of inqovi and venetoclax in acute myeloid leukemia (AML), sponsored by Rutgers University. Primary endpoint: Relapse Free Survival at 12 months. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
inqovivenetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07867626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07867626.